IMMURX LLC

Organization

LEBANON, NH, US

Business Address
16 CAVENDISH COURT SUITE 113 LEBANON NH 03766 (802) 649-8109
Mailing Address
16 CAVENDISH COURT SUITE 113 LEBANON NH 03766
State Location
NH
State of Incorporation
DE

Organizations

Please log in for detailed analytics

Patents Grantslast 30 patents

Information Patent Grant
Adjuvant combinations comprising alpha-galactosylceramide or iGb3,...
- Patent number 10,463,731
- Issue date Nov 5, 2019
- Immurx, Inc.
- Cory Ahonen
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Methods of promoting immunity to an infectious agent by administeri...
- Patent number 9,238,067
- Issue date Jan 19, 2016
- Immurx, Inc.
- Cory Ahonen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Methods of promoting antitumor immunity by administering CD40 agoni...
- Patent number 8,802,098
- Issue date Aug 12, 2014
- Immurx, Inc.
- Cory Ahonen
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Please log in for detailed analytics

Patents Applicationslast 30 patents

Information Patent Application
Adjuvant Combinations of NKT Activator, CD40 Agent, CD40 Agonist, a...
- Publication number 20160158348
- Publication date Jun 9, 2016
- IMMURX, INC.
- Cory AHONEN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

NIH Research Projectlast 12 months

processing...

Count: 10

Research Projects

Information Research Project
Preclinical Development of a Novel and Powerful Immunotherapeutic
- Application id 8418774
- Award notice date Jan 10, 2013
Information Research Project
Safe and effective anti CD154 antibodies for therapeutic intervention
- Application id 8253027
- Award notice date Mar 1, 2012
Information Research Project
Preclinical Development of a Novel and Powerful Immunotherapeutic
- Application id 8213450
- Award notice date Feb 3, 2012
Information Research Project
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
- Application id 8200942
- Award notice date Aug 2, 2011
Information Research Project
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination...
- Application id 8054408
- Award notice date Mar 14, 2011
Information Research Project
Preclinical Development of a Novel and Powerful Immunotherapeutic
- Application id 8060902
- Award notice date Jan 15, 2011
Information Research Project
Potent Vaccine Adjuvant Therapeutic
- Application id 7923075
- Award notice date Aug 25, 2010
Information Research Project
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination...
- Application id 7909550
- Award notice date Mar 30, 2010
Information Research Project
Potent Vaccine Adjuvant Therapeutic
- Application id 7611880
- Award notice date Aug 28, 2009
Information Research Project
Creation of an Anti-CD40 Superagonistic Monoclonal Antibody
- Application id 7672854
- Award notice date Apr 20, 2009

Organization

Business Address

Mailing Address

State Location

State of Incorporation

Patents Grantslast 30 patents

Adjuvant combinations comprising alpha-galactosylceramide or iGb3,...

Methods of promoting immunity to an infectious agent by administeri...

Methods of promoting antitumor immunity by administering CD40 agoni...

Patents Applicationslast 30 patents

Adjuvant Combinations of NKT Activator, CD40 Agent, CD40 Agonist, a...

NIH Research Projectlast 12 months

Research Projects

Preclinical Development of a Novel and Powerful Immunotherapeutic

Safe and effective anti CD154 antibodies for therapeutic intervention

Preclinical Development of a Novel and Powerful Immunotherapeutic

VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity

Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination...

Preclinical Development of a Novel and Powerful Immunotherapeutic

Potent Vaccine Adjuvant Therapeutic

Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination...

Potent Vaccine Adjuvant Therapeutic

Creation of an Anti-CD40 Superagonistic Monoclonal Antibody